Hien Tran, MD
Endocrinology, Diabetes & Metabolism · Round Rock, TXNPI 1821208786
Payments from drug & device makers
Across 2,174 payments — averaging $1636.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1.4M
- Eli Lilly$704K
- AbbVie$471K
- Novo Nordisk AS$437K
- Dexcom, Inc.$419K
- Senseonics, Incorporated$89K
- plus $2K from 31 others
Across 6 payments — averaging $3736.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$22K
What the payments were for
- Travel & lodging$99827%
- Food & beverage$2,67571%
- Education$842%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 272 | $1,436,358 |
| Eli Lilly | 31 | $704,494 |
| AbbVie(2 entities) | 65 | $470,715 |
| Novo Nordisk AS | 1,586 | $437,095 |
| Dexcom, Inc. | 27 | $418,719 |
| Senseonics, Incorporated | 74 | $88,765 |
| Lilly USA, LLC | 21 | $386 |
| Medtronic(2 entities) | 15 | $358 |
| Novo Nordisk | 9 | $288 |
| Amgen(2 entities) | 17 | $260 |
| AstraZeneca(2 entities) | 12 | $256 |
| Corcept Therapeutics | 4 | $69 |
| BETA Bionics, Inc. | 2 | $57 |
| Cequr Corporation | 3 | $53 |
| Xeris Pharmaceuticals, Inc. | 3 | $51 |
| Alvogen Inc | 2 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $45 |
| Amarin Pharma, Inc. | 2 | $41 |
| Mannkind Corporation | 2 | $36 |
| Bayer | 2 | $35 |
| Tandem Diabetes Care, Inc. | 3 | $34 |
| Acella Pharmaceuticals, LLC | 2 | $34 |
| Shire North American Group Inc | 2 | $33 |
| Pfizer | 2 | $31 |
| Zealand Pharma US, Inc. | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Novartis | 1 | $23 |
| Antares Pharma, Inc. | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $19 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Companion Medical, Inc. | 1 | $17 |
| Insulet Corporation | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Radius Health, Inc. | 1 | $13 |
| Merck | 1 | $12 |
How this compares
$3,558,511 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 306 | $387,963 |
| MounjaroTirzepatide | 158 | $203,477 |
| JardianceEmpagliflozin | 162 | $171,906 |
| TrulicityDulaglutide | 110 | $141,578 |
| Teriparatide | 34 | $122,633 |
| ForteoTeriparatide | 22 | $117,998 |
| TymlosAbaloparatide | 22 | $66,909 |
| Tresiba Flextouch U-200Insulin Degludec | 74 | $66,732 |
| Tresiba Flextouch U-100Insulin Degludec | 83 | $65,249 |
| JanuviaSitagliptin Phosphate | 45 | $49,723 |
| FarxigaDapagliflozin Propanediol | 39 | $40,914 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $31,675 |
| SynthroidLevothyroxine Sodium | 372 | $29,828 |
| TradjentaLinagliptin | 29 | $29,194 |
| RybelsusSemaglutide | 15 | $21,908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $386 | $465,429301 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $288 | $412,750339 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $18 | $213,645206 claims |
| Alvogen IncTeriparatide | $50 | $122,63334 claims |
| MerckJanuvia, Janumet Xr, Janumet | $12 | $74,61975 claims |
| Radius Health, Inc.Tymlos | $13 | $66,90922 claims |
| AstraZenecaFarxiga | $256 | $40,91439 claims |
| AbbVieSynthroid | $470,715 | $29,828372 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $45 | $13,74628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Round Rock
- Kerem OzerRound Rock$2.3M
- Stephanie ShawRound Rock$936K
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.